Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Emerging therapies in relapsing-remitting multiple sclerosis.

Marriott JJ, O'Connor PW.

Rev Recent Clin Trials. 2010 Sep;5(3):179-88. Review.

PMID:
20500147
2.
3.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Weinstock-Guttman B.

Am J Manag Care. 2013 Nov;19(17 Suppl):s343-54. Review.

4.

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

Thomas RH, Wakefield RA.

Am J Health Syst Pharm. 2015 Jan 1;72(1):25-38. doi: 10.2146/ajhp140023. Review.

PMID:
25511835
5.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Scott LJ.

CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000. Review.

PMID:
21790210
6.

[Current treatment of multiple sclerosis].

Csépány T.

Lege Artis Med. 2011 Feb;21(2):97-104. Review. Hungarian.

PMID:
21710707
7.

Oral treatment for multiple sclerosis.

Killestein J, Rudick RA, Polman CH.

Lancet Neurol. 2011 Nov;10(11):1026-34. doi: 10.1016/S1474-4422(11)70228-9. Review.

PMID:
22014437
8.

New management algorithms in multiple sclerosis.

Sorensen PS.

Curr Opin Neurol. 2014 Jun;27(3):246-59. doi: 10.1097/WCO.0000000000000096. Review.

PMID:
24759080
9.

[Emerging therapies for multiple sclerosis].

de Lorenzo-Pinto A, Rodríguez-González CG, Ais-Larisgoitia A.

Med Clin (Barc). 2013 Jan 19;140(2):76-82. doi: 10.1016/j.medcli.2012.05.008. Epub 2012 Jul 4. Review. Spanish.

PMID:
22766059
10.

Current management of relapsing-remitting multiple sclerosis.

Sedal L, Wilson IB, McDonald EA.

Intern Med J. 2014 Oct;44(10):950-7. doi: 10.1111/imj.12558. Review.

PMID:
25302718
11.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.

PMID:
23235682
12.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
13.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
14.

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.

J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.

PMID:
25019581
15.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group..

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

PMID:
25546031
16.

Drugs in development for relapsing multiple sclerosis.

Ali R, Nicholas RS, Muraro PA.

Drugs. 2013 May;73(7):625-50. doi: 10.1007/s40265-013-0030-6. Review.

PMID:
23609782
17.

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.

Drug Des Devel Ther. 2010 Jul 21;4:117-26. Review.

18.

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

Gold R.

CNS Drugs. 2011 Jan;25(1):37-52. doi: 10.2165/11539820-000000000-00000. Review.

PMID:
21128693
19.

Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.

Agashivala N, Kim E.

Clin Ther. 2012 Jul;34(7):1583-90. doi: 10.1016/j.clinthera.2012.06.012. Epub 2012 Jun 28.

PMID:
22749258
20.

Emerging oral drugs for multiple sclerosis.

Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C.

Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465 . Review.

PMID:
18764723

Supplemental Content

Support Center